61 results on '"Rizzardini, Giuliano"'
Search Results
2. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
3. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy
4. Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network
5. Respiratory syncytial virus burden and risk factors for severe disease in patients presenting to the emergency department with flu-like symptoms or acute respiratory failure
6. Pillars of long-term antiretroviral therapy success
7. Delayed diagnosis among patients with cutaneous and mucocutaneous leishmaniasis
8. Ongoing sporadic monkeypox cases: neutralising antibody detection in asymptomatic individuals
9. Viral bloodstream detection in mpox patients: An observational multicentric study
10. Evolution of the SARS-CoV-2 epidemic: From genomic surveillance to new health needs
11. Trend in the proportion of subjects with SARS-CoV-2 infection without COVID-19 specific symptoms among patients admitted to a COVID-19 referral hospital
12. Role of multi-site sampling in the diagnosis of human Monkeypox
13. Natural history of human Monkeypox in individuals attending a sexual health clinic in Milan, Italy
14. Hospitalisation for monkeypox in Milan, Italy
15. New challenges in human monkeypox outside Africa: A review and case report from Italy
16. Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study
17. Characterisation of baseline complement values in patients with chronic hepatitis B virus infection in the phase IIb B-clear study
18. Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy
19. Distribution of patients by guideline-defined disease phase and/ or grey zones in B-Clear, an international multicentre clinical trial
20. Persistence of Long-COVID symptoms in a heterogenous prospective cohort
21. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
22. Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: A cross-sectional study
23. One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG
24. A case of extremely prolonged viral shedding: Could cell cultures be a diagnostic tool to drive COVID-19 patient discharge?
25. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population
26. Consumption of antibiotics at an Italian university hospital during the early months of the COVID-19 pandemic: Were all antibiotic prescriptions appropriate?
27. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
28. Retinal findings in patients with COVID-19: Results from the SERPICO-19 study
29. Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings
30. Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy
31. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status
32. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study
33. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
34. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
35. Patients with Inflammatory Bowel Disease Have a Lower Risk of COVID-19: A Case-Control Study from Lombardy, Italy
36. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
37. THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance
38. THU-175-Eligibility and feasibility of hepatitis C treatment in the era of direct-acting antiviral agents: Our experience in real-world practice
39. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
40. THU-180-Treatment of genotype 3 HCV infection in the large real-life “Navigatore Lombardia” multicentre cohort: Results from three different regimens
41. THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience
42. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
43. Epidemiological and clinical characteristics of imported malaria in adults in Milan, Italy, 2010–2015
44. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
45. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
46. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
47. HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region
48. Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice
49. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome
50. Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.